Clinical Trials Logo

Clinical Trial Summary

Oral cancer represents the sixth most common cancer worldwide whilst in Pakistan it ranks the second most common cancer in either gender. Histologically, over 90% of oral cancer lesions are squamous cell carcinomas which are diagnosed on the basis of histopathological analysis. However, proliferation kinetics and nucleolar status are not clearly delineated by routine H&E examination; thus making use of various proliferation markers imperative for the purpose.

Nuclear organizer regions (AgNORs) are associated with proliferative activity and represents as a diagnostic aid in oral malignancies. Similarly, methyl green pyronin (MGP) stain has also been valuable as a complement in routine histopathological studies of several neoplastic entities.

Morphometric techniques offer an opportunity to quantify nuclear changes associated with malignancy and may provide an objective basis for grading the tumors. The present study is planned to analyze the morphometric parameters of the MGP stain in oral squamous cell carcinoma, and in their various histological grades, and to assess if the MGP staining parameters could give information on the aggressiveness of the malignant lesions of oral cavity.

Sections from thirty cases of squamous cell carcinoma along with thirty cases of normal oral mucosa will be evaluated for methyl green pyronin (MGP) and AgNOR staining. Morphometric analysis of various MGP staining and AgNOR parameters would be performed using micrometer. Statistical analysis of the results will be carried out using SPSS. Quantitative variables will be expressed as mean ± Standard Deviation. Frequencies and percentages will be given for qualitative variables.

It is hypothesized that oral squamous cell carcinoma will exhibit significantly higher MGP staining and AgNOR staining parameters than normal mucosa of the oral cavity.


Clinical Trial Description

Oral cancer, a major global health problem holds the sixth position worldwide with a marked variation in its geographic distribution. It is ranked as the third most frequent cancer in the developing world after stomach and cervical cancers. Amongst oral cancers, oral squamous cell carcinoma accounts for over 90% of the cases.

Out of the developing counties, Indo-Pak subcontinent amounts to one third of the global oral cancer burden. Carcinoma of the oral cavity in Pakistan, one of the high-risk countries is the second most frequent cancer in either gender. With differential distribution among sub-populations, it represents 8.8% of all reported cancer cases. The most predominant risk factors include tobacco smoking, betel chewing and alcohol.

Screening and specific diagnostic tools are two innovative approaches for early detection of oral cancer. Conventional oral examination and clinical evaluation remains the foundation of screening approaches whereas surgical biopsy followed by histological analysis is attributed to be the gold standard for diagnosing malignant oral lesions. Furthermore, some adjunctive techniques may contribute to the diagnosis of oral cancer. Of these vital staining, DNA analysis, chemiluminescence, tissue fluorescence, light-based detection systems and biomarkers are now on the forefront.

Biomarkers have been valuable in revealing additional information about tumor pathology, including the inactivation of tumor suppressor genes, angiogenesis, apoptosis and cell proliferation. Aberrations in proliferation kinetics are the most imperative factor during tumor progression. Three main categories of cell proliferation markers include growth fraction markers like Ki67, cycle-specific markers like PCNA(Proliferating Cellular Nuclear Antigen), and cell cycle time markers like AgNOR. During malignancy, proliferation and protein synthesis is mainly controlled by the nucleus.

Nucleolar Organizer Regions (NORs) are loops of DNA on the short arms of acrocentric chromosomes that presumably are associated with cell proliferation. Some of the NOR associated proteins are argyrophilic and can be demonstrated as black dots by the silver staining technique and the structures thus demonstrated are known as AgNORs. The AgNOR quantitative parameters provide information about the velocity of cell proliferation during cell cycle. Neoplastic progression is affected more by the rate of cell proliferation, rather than the proliferative activity per se.

Although AgNOR staining and AgNOR quantification are valuable methods in histopathological evaluation of malignancies, certain limitations have also been associated with this technique. Such AgNOR associated shortcomings include nucleolar affinity for silver stain obscuring the individual AgNORs in cases of intense staining, overlapping of variable degree between high and low grade tumors, difficulty in discerning doublets or clusters by light microscopy, misinterpreted stain deposition as proliferative activity along with some technical problems of staining and fixation.

Methyl Green Pyronin (MGP) stain is a differential stain used for selective staining of DNA and RNA. Methyl green binds specifically to deoxyribonucleic acid (DNA), staining nuclei green, while pyronin is specific for ribonucleic acid (RNA), staining nucleoli red. Methyl green pyronin stain has also been used to distinguish between proliferating and dedifferentiated non-proliferating cell nuclei. Similarly to assess the degradation of DNA in thyroid follicular epithelial cells, this stain has also proven to be useful.

Morphometry has been a significant advancement in delineating sequence of events responsible for cancer progression. Variations in nuclear and cellular size and shape have greater implications in the assessment of neoplastic lesions. Methyl Green Pyronin (MGP) stain has been attracting attention in the recent times as it has been used to evaluate various nuclear morphometric parameters in breast neoplasms. By using methyl green-pyronin staining, not only the inadequacies associated with AgNOR staining can be lessened but also the morphometric parameters for evaluating changes in the nucleus and nucleolus during carcinogenesis can be accomplished.

So far AgNOR staining appears to be a useful diagnostic tool in oral squamous cell carcinoma for examination of nucleolar structure and variations in nucleolar activity. On the other hand, MGP staining has been used in assessing the cancerous lesions of breast and thyroid gland and recently has been extended to oral lesions. However, no studies have been undertaken yet to evaluate and compare the morphometric parameters using these two stains within normal oral epithelium and oral squamous cell carcinoma. Similarly, very few studies have been undertaken regarding application of methyl green pyronin stain in oral pathologies.

Hence the current study has been planned to evaluate the morphometric parameters among normal oral epithelium and oral squamous cell carcinoma using methyl green pyronin staining; moreover these findings will also be compared with those of AgNOR staining. In this current scenario, methyl green pyronin staining and morphometric analysis may go hand in hand to provide a better diagnosis and early detection of oral cancer. ;


Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01987934
Study type Observational [Patient Registry]
Source Academy of Interdisciplinary Dental Education and Research
Contact
Status Enrolling by invitation
Phase N/A
Start date June 2013
Completion date December 2013

See also
  Status Clinical Trial Phase
Recruiting NCT04543266 - Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
Not yet recruiting NCT06438939 - NBI for Early Diagnosis of OPMD/OSCC N/A
Recruiting NCT05024383 - Dissecting the Heterogeneity of Oral Cancer Pain N/A
Recruiting NCT06031337 - Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Not yet recruiting NCT06174428 - Validity of Viome's Oral/Throat Cancer Test
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Recruiting NCT05069857 - Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients Phase 2
Not yet recruiting NCT03619304 - Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line N/A
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Recruiting NCT05893888 - Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Not yet recruiting NCT06055868 - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Not yet recruiting NCT06130007 - A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. Phase 2
Recruiting NCT05798793 - Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma Phase 3
Recruiting NCT02739204 - Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Phase 2
Completed NCT05708209 - The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
Recruiting NCT05862168 - Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial Phase 2
Recruiting NCT05451303 - Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Recruiting NCT05902455 - Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
Not yet recruiting NCT05803915 - Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy Phase 2